Literature DB >> 11543871

Slow onset of CNS drugs: can changes in protein concentration account for the delay?

M J Kuhar1, A R Joyce.   

Abstract

A 'protein regulation hypothesis' might explain the delay in reaching a maximal clinical effect, exhibited by some antipsychotic and addicting drugs. It also suggests that crucial 'effector' proteins that mediate the actions of these drugs might have half-lives of days to weeks. In this article, the rate of onset of some antipsychotic and addicting drugs will be examined and a model will be used to test if a change in the concentration of a given protein(s) could cause the drug-induced effects. This hypothesis uses a model where protein concentrations are determined by a zero-order synthesis rate and a first-order degradation rate. The model in its simplest form produces an exponential increase (or decrease) in protein concentrations over time, but reasonable extensions of the model can account for more complex mechanisms that allow for delayed time-courses and contributions of multiple proteins to the clinical effect.

Mesh:

Substances:

Year:  2001        PMID: 11543871     DOI: 10.1016/s0165-6147(00)01776-4

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  6 in total

1.  Repeated cocaine self-administration causes multiple changes in rat frontal cortex gene expression.

Authors:  Willard M Freeman; Karen Brebner; Kruti M Patel; Wendy J Lynch; David C S Roberts; Kent E Vrana
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

Review 2.  The "delayed onset" of antipsychotic action--an idea whose time has come and gone.

Authors:  Ofer Agid; Phillip Seeman; Shitij Kapur
Journal:  J Psychiatry Neurosci       Date:  2006-03       Impact factor: 6.186

3.  Modified 'Joyce model' of opioid dependence/withdrawal.

Authors:  Robert B Raffa; Ronald J Tallarida
Journal:  Eur J Pharmacol       Date:  2006-09-16       Impact factor: 4.432

4.  Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Authors:  Maryka Quik; Archana Mallela; Jason Ly; Danhui Zhang
Journal:  Mov Disord       Date:  2013-07-08       Impact factor: 10.338

5.  Measuring levels of proteins by various technologies: can we learn more by measuring turnover?

Authors:  Michael J Kuhar
Journal:  Biochem Pharmacol       Date:  2009-10-06       Impact factor: 5.858

6.  PAM-OBG: A monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma.

Authors:  Martyn A Sharpe; Sudhir Raghavan; David S Baskin
Journal:  Oncotarget       Date:  2018-05-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.